Now on opnMe: Get funded for your innovative proposals to understand TRPA1's roles in human diseases with unmet needs
08 April 2024
TRPA1 (transient receptor potential cation channel, subfamily A, member 1) is a cation channel expressed in the plasma membrane of multiple cell types, including a sub-population of primary sensory neurons as well as in non-neuronal cells such as immune cells. TRPA1 is considered a key player in the responses to a wide range of stimuli like cellular stress, tissue damage and inflammation as well as immune reactions.
The activation of TRPA1 results in an influx of extracellular calcium ions into the cell, triggering a variety of signal transduction pathways, e.g., an excitation response in neurons. Its expression outside the neuronal system implies roles in other physiological and pathophysiological conditions and novel disease indications, where the exact mechanistic link may not always be established yet. To further study the pharmacological relevance of TRPA1 and its inhibition, we offer the chance to access our TRPA1 antagonist BI-0111. This small molecule inhibits human, rodent TRPA1 with very good potency and high selectivity.
To have a chance to access BI-0111 and get funded, we invite scientists from all over the world to submit testable research proposals to the following question:
How would you propose to demonstrate the utility of our TRPA1 Antagonist BI-0111 in novel disease indications?
Should your research proposal be selected as a winner, you will be able to obtain TRPA1 antagonist BI-0111 in the amounts required for in vitro and in vivo experiments to validate your hypotheses. You will also directly interact with Boehringer Ingelheim scientists and benefit from access to their expertise. Add a funding request to your proposal, as winning scientists should expect funding of up to 250,000 euros for a fruitful research collaboration.
Submit your ideas now, as your proposal can only be accepted if they arrive by June 5, 2024, 11:59 pm PST.
No registration required for download
Subscribe to our newsletter to stay updated as we add new calls for proposals to opnMe.com
About our call for “Molecules for Collaboration”:
On opnMe, we now offer BI-0111, a potent, selective, and orally bioavailable small molecule antagonist of TRPA1 that can be used in vitro as well as in vivo. Have a chance at accessing this molecule and getting funded for your research in novel human diseases using BI-0111. Submit your proposals through June 5, 2024. Learn more...
About opnMe:
opnMe.com, the new open innovation portal of Boehringer Ingelheim, aims to accelerate research initiatives to enable new insights of disease biology in areas of high unmet medical need by sharing well-characterized molecules and offer collaborations for science. In the spirit of collaboration, our molecules are provided to the scientific community to help unlock and fulfill their full potential. These molecules are either freely available as “Molecules to Order” or applied via scientific research submissions as “Molecules for Collaboration”. As part of our third pillar, our “opn2EXPERTS” program, we also enlist scientific advice on key biologic issues to fuel further drug discovery and deliver novel solutions that benefit unmet patient needs, such as our latest call on leveraging spatial multi-omics profiling to characterize fibrotic disease mechanisms.